CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
Bharat Forge Ltd. 25/07/20241,593.85952.3007/04/2025 -40.25% 256 days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Promoters hold 66 per cent stake: Pharma penny stock jumps 8.5 per cent; Do You Own It?
DSIJ Intelligence-1
/ Categories: Trending, Penny Stocks

Promoters hold 66 per cent stake: Pharma penny stock jumps 8.5 per cent; Do You Own It?

The company has a market cap of over Rs 300 crore and the stock is up by 12.4 per cent from its 52-week low of Rs 50.42 per share.

On Monday, one of the Top Gainers on NSE, shares of Balaxi Pharmaceuticals Ltd, jumped 8.50 per cent to Rs 56.69 per share from its previous closing of Rs 52.27 per share. The stock’s 52-week high is Rs 151.45 per share and its 52-week low is Rs 50.42 per share. A total of 1.23 lakh shares changed hands on the NSE.

Balaxi Pharmaceuticals Ltd is an IPR-based pharmaceutical company that focuses on the production, stocking, selling, and supply of both branded and generic medicines. With a substantial portfolio of 610 pharmaceutical product registrations, Balaxi offers a diverse range of products, including tablets, injectables, liquids, and capsules, sourced from WHO-GMP-certified contract manufacturers located in India, China, and Portugal.

DSIJ's ‘Penny Pick’ service provides research-backed penny stock recommendations below Rs. 100. If this interests you, do download the service details here.

According to Quarterly Results, the company reported net sales of Rs 73.29 crore and net profit of Rs 5.36 crore in Q4FY24 while in its annual results (FY24), the company reported net sales of Rs 241 crore and a net loss of Rs 2 crore. The company has a debt of 32 crore, which is 11 per cent of its current market cap.

The shares of the company have a PE of 12x whereas the industry PE is 30x. As per NSE data, 66 per cent stake lies with the promoter and promoter group and the rest, about 34 per cent, is owned by public shareholders which includes FIIs & DIIs. The company has a market cap of over Rs 300 crore and the stock is up by 12.4 per cent from its 52-week low of Rs 50.42 per share.

Disclaimer: The article is for informational purposes only and not investment advice. 

Previous Article Pharma Penny Stock Below Rs 20: Company Receives Order Worth Rs 12,59,50,000 from J D Healthcare
Next Article Shares Below Rs 100: Only Buyers Were Seen In These Stocks, Locked in Upper Circuit Today
Print
62 Rate this article:
3.0
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR